TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preparation (Disclosed): Preparation of (A1) comprises reacting substituted benzo(1,2-b;4,5-b')dithiophene monomers of formula (VIII), and substituted heteroatoms containing cyclopentenyl monomers of formulae (IX) and (X) in presence of palladium catalyst to give (I).Y1, Y2 = -Sn(CH3)3, -Sn(C4H9)3 or -B(OR2)2;R2 = H or 1-10C alkyl; andZ1, Z2 = -Sn(CH3)3, -Sn(C4H9)3, -B(OR2)2, -Br or -I.Preferred Components: The organic semiconductor compounds (A1) include one of terminal functional groups of formulae (IV)-(VII).R1 = F or 1-20C perfluoroalkyl;t = 1-5;u = 1-6; andv = 1-3. Preferred Definitions:    D1 = substituted thiophene moiety of formula (II) or Q1 having 65 aromatic moieties e.g. thiophene-2,5-diyl, furan-2,5-diyl, selenophene-2,5-diyl, thiazole-2,5-diyl, oxazole-2,5-diyl, thiophene 1,1-dioxide-2,5-diyl, (1,3,4)oxadiazole-2,5-diyl, pyrazine-2,5-diyl, pyrimidine-2,5-diyl, pyridazine-2,5-diyl, pyridine-2,5-diyl, thieno(2,3-b)thiophene-2,5-diyl, thiazolo(5,4-d)thiazole-2,5-diyl, thieno(3,2-b)thiophene-2,5-diyl, isobenzofuran-4,7-diyl, benzo(c)thiophene-4,7-diyl, benzo(1,2,5)thiadiazole-4,7-diyl, dithieno(3,2-b;2',3'-d)thiophene-2,6-diyl, dibenzothiophene-3,7-diyl and isoquinoline-5,8-diyl;    R30 = 4-50C aromatic ring, 1-30C alkyl, 3-20C cycloalkyl, 1-30C alkoxy, 6-30C aryl, 7-30C arylalkyl, 2-30C heteroaryl (all optionally substituted) or H;    k = 1 or 2;    Ar1 = 4-20C aromatic ring, 4-14C heteroaromatic ring or 6-30C condensed polycyclic group including heteroaromatic ring (all optionally substituted), preferably Q1;    c, d = 1-99 mol.%; and    c+d = 100 mol.%.    SPECIFIC COMPOUNDS - 9 Compounds (I) are disclosed e.g. 2-(2,8-bis((2-ethylhexyl)oxy)-11-(4-tetradecyl-1,3-thiazol-2-yl)-4,10-dithiatricyclo(7.3.0.0(3,7))dodeca-1,3(7),5,8,11-pentaen-5-yl)-4-tetradecyl-1,3-thiazole of formula (Ia), 5-bromo-2-(11-(5-bromo-4-octyl-1,3-thiazol-2-yl)-2,8-dioctyl-4,10-dithiatricyclo(7.3.0.0(3,7))dodeca-1,3(7),5,8,11-pentaen-5-yl)-4-octyl-1,3-thiazole, 5-bromo-2-(11-(5-bromo-4-tetradecyl-1,3-thiazol-2-yl)-2,8-bis(tetradecyloxy)-4,10-dithiatricyclo(7.3.0.0(3,7))dodeca-1,3(7),5,8,11-pentaen-5-yl)-4-tetradecyl-1,3-thiazole, 2-(2,8-bis((2-ethylhexyl)oxy)-11-(4-octyl-1,3-selenazol-2-yl)-4,10-dithiatricyclo(7.3.0.0(3,7))dodeca-1,3(7),5,8,11-pentaen-5-yl)-4-octyl-1,3-selenazole and 5-bromo-2-(11-(5-bromo-1-methyl-1H-imidazol-2-yl)-2,8-bis((2-ethylhexyl)oxy)-4,10-dithiatricyclo(7.3.0.0(3,7))dodeca-1,3(7),5,8,11-pentaen-5-yl)-1-methyl-1H-imidazole.    EXAMPLE - 0.33 g (2,8-Bis((2-ethylhexyl)oxy)-11-(trimethylstannyl)-4,10-dithiatricyclo(7.3.0.0(3,7))dodeca-1(9),2,5,7,11-pentaen-5-yl)trimethylstannane and 0.39 g 2-bromo-4-tetradecylthiazole were introduced into a reactor under a nitrogen atmosphere and completely dissolved in anhydrous dimethyl formamide while heating at a relatively low temperature, and then 50 mg tetrakis(triphenylphosphine)palladium(0) was added as a polymerization catalyst and allowed to react at 85 degrees C for 24 hours. After the reaction, the reaction mixture cooled to room temperature by adding water to complete the reaction, and extracted with chloroform two times and concentrated by removing a chloroform layer with magnesium sulfate and purified to provide 0.33 g 2-(2,8-bis((2-ethylhexyl)oxy)-11-(4-tetradecyl-1,3-thiazol-2-yl)-4,10-dithiatricyclo(7.3.0.0(3,7))dodeca-1,3(7),5,8,11-pentaen-5-yl)-4-tetradecyl-1,3-thiazole.